Sanofi and Boehringer in Negotiations to Swap Businesses

Their animal health and consumer healthcare units are at play

Sanofi and Boehringer are in negotiations for a transaction to swap business units, making Sanofi one of the world's largest manufacturers of over-the-counter medicines and Boehringer the second-largest animal health company, according to a company statement and multiple news outlets.

Sanofi would receive 4.7 billion euros, or about $5.2 billion in cash for giving their animal health business to Boehringer, as well as get Boehringer’s consumer healthcare business, excluding its operations in China, under the agreement.

Germany would become a key center of Sanofi consumer healthcare business, including gastro-intestinal and cough & cold categories. Boehringer will commit to maintain business operations, R&D and manufacturing centers in France.

"Our combined Animal Health business would be well positioned for growth and emergence as a leader globally," said Andreas Barner, Chairman of the Board, Boehringer.

Their goal is to close the potential transaction in the fourth quarter of 2016, subject to appropriate regulatory approvals.

More in Package design